Xingqi Pharmaceutical products maintain national medical insurance coverage

On December 7, 2025, Shenyang Xingqi Pharmaceutical Co., Ltd. announced that 39 of its products would remain in the National Medical Insurance Drug Catalog. This includes 8 Class A and 31 Class B products, with no products being withdrawn. Key products such as Cyclosporine Eye Drops (II), Compound Electrolyte Intraocular Irrigation Solution, and Sodium Hyaluronate Eye Drops are among those retained.

The announcement also detailed a revision to the "Medical Insurance Catalog" regarding Gatifloxacin Ophthalmic Gel, where the "limited to second-line use" remark was removed. Aside from this specific adjustment, the inclusion status of the company's other products in the 2025 National Medical Insurance Catalog remains consistent with the 2024 version.

The company anticipates that the continued inclusion of its products will enhance accessibility and positively impact its operating performance in the long run. However, it notes that the short-term operating performance for the current reporting period will not be significantly affected. The new "National Medical Insurance Drug Catalog" will take effect on January 1, 2026. Future sales performance remains subject to uncertainties related to pharmaceutical industry policies and market changes.